The relevance of most genetic polymorphisms beyond CYP3A5* 1 on tacrolimus disposition
remains unclear. We constructed a predictive mixed model for tacrolimus dose-corrected …

Background The aim of this study was to compare the within-patient variability trough levels
(C o), dose-adjusted C o, and dose requirements of Prograf and Advograf with CYP3A5 …

BACKGROUND: Genetic polymorphisms of metabolism enzymes or intestinal drug
transporters may affect pharmacokinetic responses to immunosuppressive drugs in renal …

Purpose Tacrolimus is the substrate of multidrug-resistance 1 (ABCB1). However, the effect
of ABCB1 C3435T polymorphism on pharmacokinetic variables of tacrolimus is controversial …

Tacrolimus (TAC) is a first‐line immunosuppressant used to prevent organ rejection after
kidney transplantation. There is large inter‐individual variability in its pharmacokinetics …

Methods This prospective observational study includes patients of end stage renal disease
who underwent renal transplantion at our hospital during January 2012 to August 2014 …

Objective: Tacrolimus is an immunosuppressive drug with a narrow therapeutic range and
wide interindividual variation in its pharmacokinetics. Cytochrome P450 (CYP) 3A and P …

Tacrolimus (FK506) is one of the immunosuppressive drugs used effectively to prevent
allograft rejection after liver transplantation. Narrow therapeutic range and individual …

Background Tacrolimus (Tac) is the mainstay of standard immunosuppressive regime in
renal transplantation today. However, it needs regular drug level monitoring in view of …

Tacrolimus is characterized by a highly variable pharmacokinetics (PK) and a small
therapeutic window. It is metabolized specifically by the CYP3A isoenzymes. This study …